Retour

Penny Stocks To Buy? 10 Under $1 To Watch This Week

News Featured

Penny stocks under $1 to watch this week. The post Penny Stocks To Buy? 10 Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

PennyStocks • 19/04/2023 à 21:29:56
Bright Minds Biosciences Inc. Common Stock
Site internet: https://www.brightmindsbio.com
Status: Active
Info de l'entreprise

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Date de référencement2021-03-08
MarchéStocks
LocaleUS
Echange principalXNAS
TypeCS
DeviseUSD
CIK0001827401
Composite figiBBG00ZKX9FP7
Share Class figiBBG00Z61F382
Market Cap5,178,051 USD
Share Class Shares Outstanding4460000
Weighted Shares Outstanding4463837
Round Lot100
Date de mise à jour2024-09-19
Stats
5 derniers jours
18-09
17-09
16-09
13-09
12-09
Dernier
1.231
1.324
1.242
1.23
1.175
Variation
-7.3%
7.03%
0.49%
4.68%
-0.17%
Ouverture
1.328
1.237
1.236
1.175
1.177
Plus haut
1.345
1.339
1.275
1.345
1.31
Plus bas
1.345
1.335
1.275
1.345
1.31
Historique
PériodeVarPlus hautPlus bas
1 semaine
3.23%
1.31
1.275
1 mois
17.05%
1.1
1.035
3 mois
14.62%
1.06
0.96
6 mois
-3.57%
1.26
0.93
1 an
-24.18%
1.74
0.93
3 ans
-97.28%
44.75
0.93
5 ans
-97.28%
44.75
0.93
10 ans
-97.28%
44.75
0.93
Calendrier économique
19 Septembre 2024 (heure UTC) Actuel Précédent Consensus
★★
13:00
United States
SEP
1.592
1.883
★
11:30
United States
SEP 17
4.700
4.965
★
11:30
United States
★
11:30
United States
SEP 17
4.690
4.990
★
11:30
United States
★
08:30
United States
Q2
-266800000000.000
-241000000000.000
-259000000000.000
★
10:30
United States
SEP 13
58000000000.000
40000000000.000
53000000000.000
★
10:30
United States
SEP 13
-96000000000.000
★★
10:00
United States
AUG
-2.500
1.500
★★
16:30
United States
SEP 18
7100000000000.000
7115000000000.000
★
08:30
United States
SEP 15
227500.000
231000.000
★
08:30
United States
SEP
34.000
24.000
★
16:30
United States
SEP 18
3217000000000.000
3360000000000.000
Flux d'actualités
News Bright Minds Biosciences
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
Bright Minds Biosciences announced the initiation of a Phase 2 clinical trial of BMB-101, a novel 5-HT2C agonist, for the treatment of drug-resistant epilepsies. The company will host a KOL event to discuss the trial and the unmet needs in epilepsy care.
GlobeNewswire Inc. • Il y a 9 heures
News Calendar of Events
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders
GlobeNewswire Inc. • Il y a 1 année
Calendar Calendar of Events
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders
GlobeNewswire Inc. • Il y a 1 année
News Clinical Study
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders
GlobeNewswire Inc. • Il y a 1 année
News Clinical Study
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders
GlobeNewswire Inc. • Il y a 1 année
Stocks Changes in share capital and votes
Bright Minds Announces Effective Date of Share Consolidation
VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that, further to its news release on June 22, 2023, the Company will consolidate its common shares (the “Common Shares”) on a five (5) to one (1) basis (the “Consolidation”).
GlobeNewswire Inc. • Il y a 1 année
Stocks Changes in share capital and votes
Bright Minds Announces Effective Date of Share Consolidation
VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that, further to its news release on June 22, 2023, the Company will consolidate its common shares (the “Common Shares”) on a five (5) to one (1) basis (the “Consolidation”).
GlobeNewswire Inc. • Il y a 1 année
Stocks Changes in company's own shares
Bright Minds Announces Proposed Share Consolidation
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that it intends to consolidate its common shares (the “Common Shares”) on a five (5) to one (1) basis (the “Consolidation”). The Consolidation has been approved by the Company’s board of directors in accordance with the Articles of the Company.
GlobeNewswire Inc. • Il y a 1 année
Stocks Changes in company's own shares
Bright Minds Announces Proposed Share Consolidation
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that it intends to consolidate its common shares (the “Common Shares”) on a five (5) to one (1) basis (the “Consolidation”). The Consolidation has been approved by the Company’s board of directors in accordance with the Articles of the Company.
GlobeNewswire Inc. • Il y a 1 année
Stocks Featured
Penny Stocks To Buy? 10 Under $1 To Watch This Week
Penny stocks under $1 to watch this week. The post Penny Stocks To Buy? 10 Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks • Il y a 1 année
Voir tous
Actualités liées
Dernières actualités

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT